The platform provides facilities to develop of innovative drugs and combination of drugs for stratified therapies, with particular attention to orphan drugs, not patentable drugs and new formulations of administration.

MAIN INFRASTRUCTURES AND METHODOLOGIES AVAILABLE

The platform offers ethical legal and regulatory support for clinical trials of phase I and II, and it offers advice on scientific and regulatory aspects, quality assurance and intellectual propriety related to drug development.

The competence areas of platform are in neurodegenerative disorders, cardiovascular diseases, inflammation, rare diseases and oncology.

The small molecules platform interacts with other product platforms.

Animal care facilities:

• Transgenic and xenograft models from human tumors
• Behavioral models

In vivo imaging:

• NMR
• Two photon microscopy
• Micro TAC
• Micro PET

Peptides with biological activity:

• Synthesis
• Purification
• Characterization

Omics:

• Proteomics
• Metabolomics
• Genomics

Two main areas of pharmacology:

• Pharmacokinetics
• Pharmacodynamics

HTS (high-throughput screening) platforms:

• Identification and development of new therapeutic agents

Collection of chemical compounds:

• National collection of more than 150000 chemical compounds with “drug like” property

In Silico models:

• In silico models for quantitative relationship between chemical structure and biological activity, including toxicity prediction

TASK FORCE

Chair: Dr. Pietro Pichierri (ISS)
Co-Chair: Dr. Alfredo Budillon